Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

Engineered T cells call for back-up

  1. M. Teresa Villanueva
    View author publications

    You can also search for this author in PubMed  Google Scholar

Treatment with chimeric antigen receptor (CAR) T cells targeting the B-cell maturation antigen (BCMA) has shown remarkable results in patients with relapsed or refractory multiple myeloma (MM). However, most patients eventually relapse, underscoring the need for improved therapeutic approaches. Now, Díez-Alonso et al. have engineered T cells to secrete T cell–engaging (TCE) antibodies targeting BCMA on cancer cells and CD3 on T cells. In mouse models of MM, these TCE antibody secreting (STAb) T cells were more effective at eliminating target cells than traditional CAR-T cells.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 23, 252 (2024)

doi: https://doi.org/10.1038/d41573-024-00052-0

References

  1. Diez-Alonso, L. et al. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo. Sci. Transl Med. 16, eadg7962 (2024)

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links